Overview

• RxSight Q2 2025 revenue falls 4% to $33.6 mln, LDD sales drop 50%

• Net loss widens to $11.8 mln from $6.1 mln in Q2 2024

• Gross profit rises due to favorable product mix shift, operating expenses up 20%

Outlook

• Company reiterates 2025 revenue guidance of $120 mln to $130 mln

• RxSight expects 2025 gross margin between 72% and 74%

• Operating expenses for 2025 projected at $145 mln to $155 mln

• Non-cash stock-based compensation expected at $27 mln to $30 mln

Result Drivers

• LAL SALES - 13% increase in Light Adjustable Lens sales contributed to higher gross profit margin

• LDD SALES DECLINE - 50% decrease in Light Delivery Device sales impacted overall revenue

• FDA APPROVAL - Expansion of LAL dioptric power range and new software updates received FDA approval

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 8 "hold" and 2 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

• Wall Street's median 12-month price target for Rxsight Inc is $9.00, about 16.1% above its August 6 closing price of $7.55

Press Release: ID:nGNX9BnXqC

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)